Inhibitors of PI3K p-delta 110 for use in delivery of viruses in the treatment of cancer

Patent metadata

Field	Value
Publication number	US-11351209-B2
Application number	US-201716069101-A
Country	US
Kind code	B2
Filing date	Jan 11, 2017
Priority date	Jan 11, 2016
Publication date	Jun 7, 2022
Grant date	Jun 7, 2022

Abstract

The present invention provides a composition comprising a phosphatidylinositol 3-kinase (PI3K) inhibitor and a modified virus for separate, subsequent or simultaneous use in the treatment of cancer, wherein the modified virus is for intravenous administration.

First claim

The invention claimed is:

1. A method of treating cancer in a subject in need thereof comprising the steps of:
administering a composition comprising a phosphatidylinositol 3-kinase (PI3K) inhibitor; and subsequently:
administering a composition comprising a TK-deficient vaccinia virus, in which the TK-deficient vaccinia virus is administered intravenously.

2. The method of claim 1 , wherein the phosphatidylinositol 3-kinase delta (PI3K delta) inhibitor is selected from the group consisting of: IC-87114, PI-103, TGX221, A66, AS 604850, Idelalisib, Wortmannin, Alpelisib, Buparlisib, Copanlisib, Duvelisib, Rigosertib, and Taselisib, or a derivative thereof or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the TK-deficient vaccinia virus is modified by the insertion of a gene encoding a therapeutic agent, or the deletion, or inactivation by insertion, of a viral gene.

4. The method of claim 1 , wherein the cancer is selected from the group consisting of lung cancer, liver cancer, breast cancer, bladder cancer, colon cancer, rectal cancer, pancreatic cancer, skin cancer, stomach cancer, prostate cancer, bone cancer, adenocarcinoma, osteosarcoma, ovarian cancer, uterine cancer, testicular cancer, neuroendocrine cancer, endocrine cancer, thymus cancer, thyroid cancer, renal cancer, head and neck cancer, esophageal cancer, a peripheral central nervous system cancer or brain cancer.

5. The method of claim 1 , wherein the method further comprises administering an additional anti-cancer agent or cytostatic drug.

6. The method of claim 4 , wherein the skin cancer is melanoma, basal cell carcinoma, or squamous cell carcinoma.

Assignees

• Univ London Queen Mary

Inventors

• Wang Yaohe
• Ferguson Mark
• Lemoine Nicholas R

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K31/52

  Purines, e.g. adenine · CPC title

• A61K35/768

  Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766 · CPC title